Back to News
Market Impact: 0.3
Halozyme Wins Dutch Patent Case Against Merck Over Keytruda SC
Source: Nasdaq
Legal & LitigationPatents & Intellectual PropertyHealthcare & Biotech
The specialised Dutch patent court in The Hague found that Merck infringed Halozyme Therapeutics’ EP622 patent through its subcutaneous formulation of Keytruda. The report provides no information on damages, remedies, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
HALO0.70
MRK-0.70
More News
- Moderna options activity surges as Nasdaq-100 inclusion and melanoma data drive call buying
- Why Moderna Stock Surged Today
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- Trump created a committee to dig into the Fed's Lisa Cook. What is it and what comes next?
- Tesla’s ‘Full Self-Driving’ Becomes ‘Assisted Driving’ in Europe
- Teva wins FDA approval for monthly schizophrenia injection Weltruza